Utama › Kanser Payudara Triple-Negatif › North Carolina › Durham
Kajian klinikal Kanser Payudara Triple-Negatif di Durham, NC
12 kajian untuk Kanser Payudara Triple-Negatif sedang mencari peserta di lokasi dalam dan sekitar Durham (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Mengambil pesertaFasa 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauh
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Mengambil pesertaFasa 3
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Mengambil pesertaFasa 2
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Mengambil pesertaFasa 2/3
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Mengambil pesertaFasa 2
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Mengambil pesertaFasa 1
- University of North Carolina, Chapel Hill · 10 mi jauh
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Mengambil pesertaFasa 1
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Mengambil pesertaFasa 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauh
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
Mengambil pesertaFasa 2
- University of North Carolina, Chapel Hill · 10 mi jauh
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Mengambil pesertaFasa 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
A Study of NX-1607 in Adults With Advanced Malignancies
Mengambil pesertaFasa 1
- University of North Carolina, Chapel Hill · 10 mi jauh
Kajian Kanser Payudara Triple-Negatif di bandar lain
- Houston, TX42 kajian
- New York City, NY31 kajian
- Nashville, TN28 kajian
- Los Angeles, CA27 kajian
- Boston, MA26 kajian
- San Antonio, TX23 kajian
- St. Louis, MO21 kajian
- Arlington, VA20 kajian
- Atlanta, GA20 kajian
- Dallas, TX18 kajian
- Chicago, IL16 kajian
- Columbus, OH16 kajian
Kajian lain di Durham
- Kanser Payudara64 kajian
- Kanser (semua jenis)58 kajian
- Kanser Paru-paru Bukan Sel Kecil39 kajian
- Mieloma Pelbagai37 kajian
- Leukemia Mieloid Akut33 kajian
- Kanser Metastatik33 kajian
- Kanser Prostat32 kajian
- Kanser Paru-paru32 kajian
- Kanser Kolorektal28 kajian
- Kanser Ovari27 kajian
- Leukemia Limfositik Kronik27 kajian
- Kegagalan Jantung26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.